EP
ADMA icon

Essential Partners’s ADMA Biologics ADMA Stock Holding History

Essential Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.79K Buy
572
+521
+1,022% +$4.75K ﹤0.01% 1562
2026
Q1 		$460 Buy
51
+45
+750% +$710 ﹤0.01% 2460
2025
Q4 		$109 Sell
6
-73
-92% -$1.23K ﹤0.01% 2535
2025
Q3 		$1.16K Sell
79
-839
-91% -$14.4K ﹤0.01% 1979
2025
Q2 		$16.7K Buy
+918
New +$18.7K 0.01% 721

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Essential Partners's ADMA Position: Q2 2026 in Review

Essential Partners increased its ADMA Biologics (ADMA) stake by 1,022% in Q2 2026, buying an estimated $4.75K and bringing the position to 572 shares worth $4.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Essential Partners first reported a position in ADMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $16.7K in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Essential Partners held 572 shares of ADMA Biologics worth $4.79K as of Q2 2026.
  • Essential Partners bought 521 ADMA Biologics shares in Q2 2026, an estimated $4.75K.
  • ADMA Biologics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1562 holding.
  • Essential Partners first reported a position in ADMA Biologics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's ADMA Biologics position peaked at $16.7K in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.